depression
Research suggests physical activity can reduce depressive symptoms.
A large review adds weight to an old idea: movement can help ease depression. Here’s how to think about exercise as part of treatment and recovery.
Advanced TMS Protocol Demonstrates Increased Remission Rates In Depression
(MENAFN - PR Newswire) Key findings at a glance: A recent study evaluated 600 adults with depression. Over 80% of participants experienced significant symptom improvement with a novel ...
Single dose of powerful psychedelic cuts depression symptoms in clinical study
Breakthrough study finds single dose of psychedelics significantly reduced depression symptoms in clinical trial, with effects lasting up to six months.
Postpartum depression in dads is common – we can now spot and treat it
Fathers may get postpartum depression at a similar rate to mothers, but it’s often overlooked. At last, the way we diagnose and treat it is improving, for the good of the whole family
Magnus Medical Moves to Protect Intellectual Property Behind Breakthrough SAINT Accelerated Depression Therapy
BURLINGAME, Calif.--(BUSINESS WIRE)--Feb 18, 2026--
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
LONDON & NEW YORK--(BUSINESS WIRE)--Feb 17, 2026--
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
WILMINGTON, Del., Feb. 17, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has completed an in-person Type C guidance meeting at the headquarters of the US Food and Drug Administration. The meeting was attended by leaders of the FDA Division of Psychiatry Products, the FDA Office of Neuroscience, and the FDA Center for Drug Evaluation and Research.
Biomednewsbreaks - Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting For NRX-100 NDA Pathway
(MENAFN - Investor Brand Network)NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S. Food and Drug Administration, attended by leadership ...
Instanosis Xylazine Rapid Test (Urine) Granted FDA Breakthrough Device Designation
PHILADELPHIA--(BUSINESS WIRE)--Feb 17, 2026--
Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2A Trial Of SPL026 In Major Depressive Disorder
(MENAFN - GlobeNewsWire - Nasdaq) Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as ...
FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRDHEIDELBERG, Germany, Feb. 17, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or "the Company"), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
LONDON & NEW YORK--(BUSINESS WIRE)--Feb 16, 2026--